Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease (ESRD). To evaluate the efficacy and safety of different types of mineralocorticoid receptor antagonists (MRAs) in diabetic kidney disease patients, we conducted this network meta-analysis by performing a systematic...
Main Authors: | Yichuan Wu, Huanjia Lin, Yuan Tao, Ying Xu, Jiaqi Chen, Yijie Jia, Zongji Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.967317/full |
Similar Items
-
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2021-10-01) -
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01) -
Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients
by: Sun Z, et al.
Published: (2023-01-01) -
Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01) -
The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
by: Eqerem Hasani, et al.
Published: (2022-01-01)